Delivery of cancer therapies by synthetic and bio-inspired nanovectors

Briolay, Tina; Petithomme, Tacien; Fouet, Morgane; Nguyen-Pham, Nelly; Blanquart, Christophe; Boisgerault, Nicolas

doi:10.1186/s12943-021-01346-2

Cited by 73 publications

(53 citation statements)

References 315 publications

(384 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, JCPyV VLPs can be guided by a cell surface marker binding peptide for the specific delivery and transduction of a gene of interest expressed by a tissue-specific promoter in a targeted cell type. VLPs retain the characteristics of virus-specific binding to host cells, but are allowed for genetic or chemical modification to alter the tropism or increase their binding efficiency to their nature host cells 33 , 34 . For example, the specific cellular targeting of MS2 VLPs are demonstrated through attachment of a tissue specific nucleic acid aptamers 35 .…”

Section: Discussionmentioning

confidence: 99%

Peptide-guided JC polyomavirus-like particles specifically target bladder cancer cells for gene therapy

Lai

Fang

Chou

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The ultimate goal of gene delivery vectors is to establish specific and effective treatments for human diseases. We previously demonstrated that human JC polyomavirus (JCPyV) virus-like particles (VLPs) can package and deliver exogenous DNA into susceptible cells for gene expression. For tissue-specific targeting in this study, JCPyV VLPs were conjugated with a specific peptide for bladder cancer (SPB) that specifically binds to bladder cancer cells. The suicide gene thymidine kinase was packaged and delivered by SPB-conjugated VLPs (VLP-SPBs). Expression of the suicide gene was detected only in human bladder cancer cells and not in lung cancer or neuroblastoma cells susceptible to JCPyV VLP infection in vitro and in vivo, demonstrating the target specificity of VLP-SPBs. The gene transduction efficiency of VLP-SPBs was approximately 100 times greater than that of VLPs without the conjugated peptide. JCPyV VLPs can be specifically guided to target particular cell types when tagged with a ligand molecule that binds to a cell surface marker, thereby improving gene therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Peptide-guided JC polyomavirus-like particles specifically target bladder cancer cells for gene therapy

Lai

Fang

Chou

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Research that targeting oncogenic mRNAs by siRNA is under evaluation [ 68 ]. Gene therapy can also induce cell death by delivering transgene or cell death-triggering gene to tumor cells [ 69 ].…”

Section: Nanomaterials Used For Cancer Treatmentmentioning

confidence: 99%

Nanomaterials for cancer therapy: current progress and perspectives

et al. 2021

View full text Add to dashboard Cite

Cancer is a disease with complex pathological process. Current chemotherapy faces problems such as lack of specificity, cytotoxicity, induction of multi-drug resistance and stem-like cells growth. Nanomaterials are materials in the nanorange 1–100 nm which possess unique optical, magnetic, and electrical properties. Nanomaterials used in cancer therapy can be classified into several main categories. Targeting cancer cells, tumor microenvironment, and immune system, these nanomaterials have been modified for a wide range of cancer therapies to overcome toxicity and lack of specificity, enhance drug capacity as well as bioavailability. Although the number of studies has been increasing, the number of approved nano-drugs has not increased much over the years. To better improve clinical translation, further research is needed for targeted drug delivery by nano-carriers to reduce toxicity, enhance permeability and retention effects, and minimize the shielding effect of protein corona. This review summarizes novel nanomaterials fabricated in research and clinical use, discusses current limitations and obstacles that hinder the translation from research to clinical use, and provides suggestions for more efficient adoption of nanomaterials in cancer therapy.

show abstract

“…Bio-derived vesicles have drawn interest in drug and gene delivery research due to their low immunogenicity, high cellular uptake and excellent loading capacity for various cargos. 178 Recently, Kim et al developed tumorderived exosomes for Cas9 plasmid delivery. 179 They found that tumor-derived exosomes outperformed epithelial cellderived exosomes in vivo due to their cell tropism.…”

Section: Reviewmentioning

confidence: 99%